A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus Concentrations
HIV Infections
About this trial
This is an observational trial for HIV Infections focused on measuring Cytokines, Gene Regulation, Immunization, Influenza, Pathogenesis
Eligibility Criteria
PATIENT VOLUNTEERS: HIV positive. CD4 cells greater than 200, obtained within the prior 2 months. Age greater than 18 years. Willing and able to participate in study. No immunomodulatory therapy, including other vaccinations within the prior 4 weeks. Stable therapy on G-CSF and/or thalidomide permitted. No contraindications for influenza vaccination. No clinical conditions that would place the patient at undo risk from the mandated protocol blood draws. No recent (less than 4 weeks) changes in antiviral therapy or change in antiviral therapy anticipated during the 3 week duration of the study. No history of recent (less than 4 weeks) or intercurrent blood transfusion or cytotoxic chemotherapy. Hemoglobin greater than 9.0 g/dl. Total volume of blood otherwise drawn should not exceed 500 ml over 6 weeks. No upper respiratory infections or other acute illnesses within the prior 2 weeks. CONTROL NORMAL VOLUNTEERS: Age greater than 18 years. Willing and able to participate in study. Healthy. No ongoing condition or recent (less than 4 weeks) illness requiring a physician's care. No upper respiratory infections or other acute illnesses within the prior 2 weeks. Total volume of blood drawn should not exceed 500 ml over 6 weeks. Not taking any prescription medications.
Sites / Locations
- National Cancer Institute (NCI)